News
AIMD
0.5449
+2.23%
0.0119
AINOS INC - VELDONA ORAL INTERFERON RECEIVES APPROVAL TO BEGIN HUMAN TRIALS IN TAIWAN
Reuters · 4d ago
Ainos provides mid-year update outlining milestones
TipRanks · 4d ago
Ainos announces 2H25 execution roadmap
TipRanks · 4d ago
Weekly Report: what happened at AIMD last week (0609-0613)?
Weekly Report · 4d ago
Weekly Report: what happened at AIMD last week (0602-0606)?
Weekly Report · 06/09 10:07
Weekly Report: what happened at AIMD last week (0526-0530)?
Weekly Report · 06/02 10:11
Ainos announces data on AI Nose in hygiene monitoring
TipRanks · 05/29 12:30
Weekly Report: what happened at AIMD last week (0519-0523)?
Weekly Report · 05/26 10:11
Ainos showcases AI Nose technology at COMPUTEX 2025
TipRanks · 05/22 12:30
Ainos reports interim results in VELDONA trial for FCGS
TipRanks · 05/19 12:26
Weekly Report: what happened at AIMD last week (0512-0516)?
Weekly Report · 05/19 10:06
Ainos, Inc. Reports Significant Revenue Growth in Q1 2025
TipRanks · 05/13 04:17
Ainos GAAP EPS of -$0.21, revenue of $106M
Seeking Alpha · 05/12 17:32
Ainos reports Q1 EPS (21c) vs. (57c) last year
TipRanks · 05/12 13:21
Ainos Q1 EPS $(0.21) Up From $(0.57) YoY, Sales $106.21K Up From $20.73K YoY
Benzinga · 05/12 12:13
AINOS Q1 BASIC EPS USD -0.21
Reuters · 05/12 12:01
Weekly Report: what happened at AIMD last week (0505-0509)?
Weekly Report · 05/12 10:07
Weekly Report: what happened at AIMD last week (0428-0502)?
Weekly Report · 05/05 10:07
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 04/30 21:05
Ainos forms partnership with ASE Chung Li
TipRanks · 04/30 13:29
More
Webull provides a variety of real-time AIMD stock news. You can receive the latest news about Ainos Inc through multiple platforms. This information may help you make smarter investment decisions.
About AIMD
Ainos, Inc. is a diversified healthcare company, which is focused on the development of point-of-care testing (POCT), low-dose VELDONA interferon therapeutics and synthetic Ribonucleic Acid (RNA)-driven preventative medicine. Its product pipeline includes VELDONA clinical-stage human therapeutics, VELDONA Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by its AI Nose technology platform. VELDONA Pet is formulated to address a variety of health issues in dogs and cats, including skin, gum, emotion, discomfort caused by allergies, eye, and weight-related issues. Its pipeline of products, which are under development, includes VELDONA human and animal drugs, VOC POCT-Ainos Flora, VOC platform-NISD co-development, VOC POCT-Ainos Pen, VOC POCT-CHS430 and Synthetic RNA. VELDONA human drugs are the high-priority programs include oral warts for human immunodeficiency virus seropositive patients, common cold, influenza and Sjogrens syndrome.